98 related articles for article (PubMed ID: 278642)
1. Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.
Lerner HJ
Cancer Treat Rep; 1978 Aug; 62(8):1135-8. PubMed ID: 278642
[TBL] [Abstract][Full Text] [Related]
2. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.
Patt DA; Duan Z; Fang S; Hortobagyi GN; Giordano SH
J Clin Oncol; 2007 Sep; 25(25):3871-6. PubMed ID: 17664457
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemia following non-Hodgkin's lymphoma: danger of prolonged use of chlorambucil as maintenance therapy.
Dumont J; Thiery JP; Mazabraud A; Natali JC; Trapet P; Vilcoq JR
Nouv Rev Fr Hematol (1978); 1980; 22(4):391-404. PubMed ID: 6942388
[TBL] [Abstract][Full Text] [Related]
5. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
Kröger N; Damon L; Zander AR; Wandt H; Derigs G; Ferrante P; Demirer T; Rosti G; ; ;
Bone Marrow Transplant; 2003 Dec; 32(12):1153-7. PubMed ID: 14647269
[TBL] [Abstract][Full Text] [Related]
6. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
[TBL] [Abstract][Full Text] [Related]
7. Acute leukemia in advanced ovarian carcinoma after treatment with alkylating agents.
Sotrel G; Jafari K; Lash AF; Stepto RC
Obstet Gynecol; 1976 Jan; 47(1):67S-71S. PubMed ID: 1061006
[TBL] [Abstract][Full Text] [Related]
8. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
Praga C; Bergh J; Bliss J; Bonneterre J; Cesana B; Coombes RC; Fargeot P; Folin A; Fumoleau P; Giuliani R; Kerbrat P; Hery M; Nilsson J; Onida F; Piccart M; Shepherd L; Therasse P; Wils J; Rogers D
J Clin Oncol; 2005 Jun; 23(18):4179-91. PubMed ID: 15961765
[TBL] [Abstract][Full Text] [Related]
9. Leukemia incidence following primary breast carcinoma treatment.
Kaplan HG; Malmgren JA; Atwood M
Cancer; 2004 Oct; 101(7):1529-36. PubMed ID: 15378478
[TBL] [Abstract][Full Text] [Related]
10. [Acute myelogenous leukemia after cytostatic therapy of breast cancer].
Asbjørnsen G; Godal HC; Myhre K
Tidsskr Nor Laegeforen; 1981 Feb; 101(6):387-8. PubMed ID: 6938080
[No Abstract] [Full Text] [Related]
11. [Acute leukemia secondary to the treatment of multiple sclerosis with chlorambucil].
Aymard JP; Witz F; Conroy T; Lederlin P; Humbert JC; Barroche G; Streiff F
Rev Neurol (Paris); 1985; 141(2):152-4. PubMed ID: 3858929
[TBL] [Abstract][Full Text] [Related]
12. Is age an independent risk factor for chemically induced acute myelogenous leukemia in children?
Pyatt DW; Aylward LL; Hays SM
J Toxicol Environ Health B Crit Rev; 2007; 10(5):379-400. PubMed ID: 17687725
[TBL] [Abstract][Full Text] [Related]
13. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
14. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials.
Greene MH; Boice JD; Greer BE; Blessing JA; Dembo AJ
N Engl J Med; 1982 Dec; 307(23):1416-21. PubMed ID: 6752720
[TBL] [Abstract][Full Text] [Related]
15. [Therapy-related acute myeloid leukemia with 11q23 abnormality due to paclitaxel coexisting with bone marrow metastasis of breast cancer].
Saito M; Mori A; Irie T; Tanaka M; Morioka M
Rinsho Ketsueki; 2009 Mar; 50(3):192-6. PubMed ID: 19352087
[TBL] [Abstract][Full Text] [Related]
16. Leukemia following chemotherapy for breast cancer.
Curtis RE; Boice JD; Moloney WC; Ries LG; Flannery JT
Cancer Res; 1990 May; 50(9):2741-6. PubMed ID: 2328500
[TBL] [Abstract][Full Text] [Related]
17. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
[TBL] [Abstract][Full Text] [Related]
18. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
Muss HB; Berry DA; Cirrincione C; Budman DR; Henderson IC; Citron ML; Norton L; Winer EP; Hudis CA;
J Clin Oncol; 2007 Aug; 25(24):3699-704. PubMed ID: 17704418
[TBL] [Abstract][Full Text] [Related]
19. Acute leukemia after alkylating-agent therapy of ovarian cancer.
Reimer RR; Hoover R; Fraumeni JF; Young RC
N Engl J Med; 1977 Jul; 297(4):177-81. PubMed ID: 406560
[TBL] [Abstract][Full Text] [Related]
20. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
